Flomics
Flomics is a biotechnology company specializing in genomics and liquid biopsy. By integrating Next-Generation Sequencing (NGS) with machine learning, Flomics has developed a liquid biopsy test that…
Flomics
Flomics is a biotechnology company specializing in genomics and liquid biopsy. By integrating Next-Generation Sequencing (NGS) with machine learning, Flomics has developed a liquid biopsy test that…
TL;DR
Headquarters: Barcelona, Spain
Core technology: cfRNA-based liquid biopsy using NGS + machine learning (Stratus® platform)
Founded: 2018
Team size (approx.): 23 employees
Recent funding: €1.1M seed round announced March 2024 (company release)
Company Overview
Problem Domain
Early detection and biomarker discovery for cancer and complex diseases using circulating cell-free RNA and NGS-based assays.
Founded
2018
Industry
Biotechnology Research
Tech Stack
Funding Track Record
€1.1M
Supported by Decelera Ventures, FCR, Histemi Inversiones and additional backers; company announcement
$2.3M (total across two rounds reported by Dealroom)
Aggregate total reported by Dealroom
Investor Signal
“Backers named in company release include Decelera Ventures, FCR, Histemi Inversiones and a U.S. family office; also ran a crowdfunding campaign with Capital Cell”
Founders
What we do
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |